Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
Want to see ATAI full AI Analyst Report?
Top Page
Atai Beckley N.V.
(NASDAQ:ATAI)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.50
▲(11.66% Upside)
Action:Reiterated
Date:05/16/26
The score is mainly held down by weak financial performance driven by minimal revenue scale, very large losses, and significant ongoing cash burn, despite a low-leverage balance sheet. Technical indicators are mixed and do not provide a strong positive catalyst, and valuation remains unattractive due to negative earnings and no dividend support.
Positive Factors
Low leverage / ample equity
Very low net leverage and ~ $199M of equity versus ~$265M of assets provide durable financial flexibility. For a cash-burning clinical-stage biotech this reduces near-term refinancing risk, allows continued R&D investment without immediate debt strain, and supports optionality for partnerships or deals over the next months.
Negative Factors
Very small, declining revenue base
Revenue of roughly $3.5M TTM and a recent decline indicate the company lacks material commercial cash flow. With no scalable product revenue, ongoing operating costs must be funded externally; this structural revenue weakness limits self‑funding ability and increases dependence on financing or partner milestones over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / ample equity
Very low net leverage and ~ $199M of equity versus ~$265M of assets provide durable financial flexibility. For a cash-burning clinical-stage biotech this reduces near-term refinancing risk, allows continued R&D investment without immediate debt strain, and supports optionality for partnerships or deals over the next months.
Read all positive factors
Atai Beckley N.V. (ATAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.67B
Dividend YieldN/A
Average Volume (3M)4.81M
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees99
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding368,166,700
10 Day Avg. Volume4,706,750
30 Day Avg. Volume4,811,811
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue466.37
Enterprise Value/Gross Profit568.57
Enterprise Value/Ebitda-12.81
Forecast
1Y Price Target
$14.90Price Target Upside269.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Atai Beckley N.V. Business Overview & Revenue Model
Company Description
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulatio...
How the Company Makes Money
ATAI is a clinical-stage company and, as such, it does not primarily generate recurring revenue from commercialized products. Its potential and historical sources of cash inflow are typically tied to its drug-development platform: (1) partnering a...
Atai Beckley N.V. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.49M | 4.09M | 308.00K | 314.00K | 233.00K | 20.38M |
| Gross Profit | 2.86M | 3.08M | -165.00K | -5.00K | 65.00K | 20.33M |
| EBITDA | -126.97M | -98.75M | -102.22M | -125.15M | -144.26M | -120.28M |
| Net Income | -663.40M | -660.05M | -149.27M | -40.22M | -152.38M | -167.81M |
Balance Sheet | ||||||
| Total Assets | 264.88M | 310.54M | 159.39M | 293.48M | 305.44M | 414.17M |
| Cash, Cash Equivalents and Short-Term Investments | 230.77M | 256.04M | 62.33M | 179.26M | 273.11M | 362.27M |
| Total Debt | 2.00M | 2.07M | 24.71M | 19.14M | 15.34M | 743.00K |
| Total Liabilities | 66.10M | 88.54M | 42.83M | 49.16M | 39.67M | 28.21M |
| Stockholders Equity | 198.68M | 221.87M | 116.30M | 242.96M | 260.74M | 376.91M |
Cash Flow | ||||||
| Free Cash Flow | -117.19M | -103.58M | -82.53M | -84.71M | -105.49M | -64.37M |
| Operating Cash Flow | -106.60M | -102.67M | -82.44M | -84.12M | -104.47M | -63.25M |
| Investing Cash Flow | -120.02M | -109.13M | 59.17M | -53.30M | -86.85M | -81.28M |
| Financing Cash Flow | 213.28M | 269.48M | 5.37M | -8.36M | 20.79M | 409.86M |
Atai Beckley N.V. Technical Analysis
Positive
4.03
Price Trends
4.13
Positive
3.95
Positive
4.32
Positive
Market Momentum
0.14
Negative
56.08
Neutral
56.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATAI, the sentiment is Positive. The current price of 4.03 is below the 20-day moving average (MA) of 4.28, below the 50-day MA of 4.13, and below the 200-day MA of 4.32, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 56.08 is Neutral, neither overbought nor oversold. The STOCH value of 56.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATAI.
Atai Beckley N.V. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $7.78B | -23.42 | -43.02% | ― | -100.00% | -24.90% | |
55 Neutral | $1.11B | -6.64 | -56.41% | ― | -31.58% | -27.41% | |
52 Neutral | $2.00B | -9.28 | -87.00% | ― | -36.24% | 11.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.67B | -1.54 | -366.49% | ― | ― | ― | |
46 Neutral | $811.58M | -6.26 | -35.33% | ― | ― | 23.91% |
* Healthcare Sector Average
ATAI
Atai Beckley N.V.
4.50
2.02
81.45%
NKTR
Nektar Therapeutics
59.31
49.19
485.95%
WVE
Wave Life Sciences
6.09
-0.66
-9.78%
ORIC
Oric Pharmaceuticals
8.02
-1.14
-12.45%
PRAX
Praxis Precision Medicines
264.75
222.49
526.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.